Therapeutic Effect of Isoladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in Population

• Status: Not yet recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

All patients who met the inclusion criteria and agreed to participate in the study underwent baseline capsule endoscopy. Patients with intestinal mucosal injury detected during the initial capsule endoscopy were randomly divided into isoladin maleate group or magnesium aluminum carbonate control group using computer-generated random numbers. Patients in the isoladine maleate group received 4 mg isoladine maleate (Gesellon, Japan) every morning for 4 weeks (or 8 weeks, duration to be determined); Magnesium aluminum carbonate control group received 1 g magnesium aluminum carbonate every morning, afternoon and evening for 4 weeks (or 8 weeks, course to be determined). After treatment, capsule endoscopy was performed again to evaluate the healing of intestinal mucosa.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lee's Pharmaceutical Limited
• Treatments: Hydrotalcite; Irsogladine

Criteria

Inclusion Criteria:

1. Within 4 weeks before the study, NSAIDs were taken at least once a day with symptoms and signs of abdominal discomfort, such as abdominal pain, abdominal distension and dyspepsia;

2. During the 8-week observation period of the study, NSAIDs will continue to be used in the same protocol (whether to stop NSAIDs during the study remains to be determined);

3. Patients taking antisecretory drugs such as proton pump inhibitors or H2 receptor antagonists and gastric mucosal protectors such as rebapide or tiprexone were eligible;

4. Willing to sign informed consent

Exclusion Criteria:

1. Active gastrointestinal bleeding;

2. Taking more than two NSAIDs, anticoagulants, steroid hormones or prostaglandin derivatives;

3. Have a history of gastrointestinal surgery except appendectomy;

4. Suspected small bowel obstruction;

5. gastroduodenal ulcer;

6. Severe cardiopulmonary diseases (NYHA grade IV cardiac function or respiratory failure);

7. Significant renal impairment (serum creatinine ≥2 mg/dL or glomerular filtration rate GFR<40 mL/min);

8. Liver insufficiency (liver function: total bilirubin >ULN, ASpartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≥ 2.0 × ULN);

9. Confirmed or suspected combined with malignant tumor;

10. pregnant and lactation women or women who do not exclude the possibility of pregnancy;

11. Drug addicts or alcoholics;

12. Participants in other drug trials within 3 months;

13. The researcher considers it unsuitable for participants